Changing to core biopsy in an NHS breast screening unit.
We recently changed from using fine needle aspiration cytology to using core biopsy exclusively in the assessment of screen detected abnormalities. Two hundred and two biopsies (1% of women screened) were performed. Surgical histological confirmation was obtained in 111 patients (101 malignant and 10 benign). The remaining patients were either returned to standard 3-yearly screening or early repeat screening after 1 year. Analysis of the results was performed in accordance with the standards specified in the National Health Service Breast Screening Programme (NHSBSP) Publication Number 22. Absolute sensitivity was 89.3%, complete sensitivity was 93.2%, specificity (including patients undergoing both surgical excision and follow-up) was 88.7%. The predictive value of a positive (malignant) core biopsy result was 100%. The false negative rate was 3.9%. Twelve (5.9%) biopsies were classified inadequate for diagnosis. Core biopsy is a safe and accurate way of assessing screen detected abnormalities and can be used as a substitute for fine needle aspiration cytology with results that exceed the National Health Service Breast Screening Programme target standards, even in the learning phase.
Britton
P D
PD
Department of Radiology, Addenbrooke's Hospital and Cambridge University, UK.
Flower
C D
CD
Freeman
A H
AH
Sinnatamby
R
R
Warren
R
R
Goddard
M J
MJ
Wight
D G
DG
Bobrow
L
L
D001706:Biopsy / Q000379:methods*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000517:prevention & control; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008327:Mammography; D008403:Mass Screening; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013222:State Medicine; D018084:Ultrasonography, Interventional; D016217:Ultrasonography, Mammary; D006113:United Kingdom